ÅsHild Bjørnerem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
ÅsHild Bjørnerem has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Bjørn Straume
Institute of Community Medicine, University of Tromsø, Tromsø, Norway
4 shared publicationsVinjar Fønnebø
Institute of Community Medicine, University of Tromsø, Tromsø, Norway
3 shared publicationsGro K. R. Berntsen
Institute of Community Medicine, University of Tromsø, Tromsø, Norway
2 shared publicationsPål Øian
2 shared publicationsPål Øian
Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
2 shared publicationsEgo Seeman
1 shared publication
Latest Publications
- 6 July 2007
- Published by Springer Nature in Calcified Tissue International
- Vol. 81 (2) , 65-72
Circulating Sex Steroids, Sex Hormone-Binding Globulin, and Longitudinal Changes in Forearm Bone Mineral Density in Postmenopausal Women and Men: The Tromsø Study
Bone loss during advancing age in women and men is partly the result of sex steroid deficiency. As the contribution of circulating sex steroids and sex hormone-binding globulin (SHBG) to bone loss remains uncertain, we sought to determine whether levels of sex steroids or SHBG predict change in bone mineral density (BMD) in women and men. A population-based study in the city of Tromsø of 6.5 years’ duration (range 5.4-7.4) included 927 postmenopausal women aged 37–80 years and 894 men aged 25–80 years. Total estradiol and testosterone, calculated free levels, and SHBG were measured at baseline, and BMD change at the distal forearm was determined using BMD measurements in 1994–1995 and 2001. Bone loss was detected in postmenopausal women and men. Free estradiol and SHBG predicted age-adjusted bone loss in postmenopausal women, but only free estradiol was associated after further adjustment for body mass index and smoking in mixed models (P < 0.05). After same adjustment, only SHBG persisted as a significant independent predictor of bone loss in men (P < 0.001). However, only 1% of the variance in bone loss was accounted for by these measurements. We therefore conclude that the relations between sex steroids and bone loss are weak and measurements of sex steroids are unlikely to assist in clinical decision making.
- 6 July 2007
- Published by Springer Nature in Calcified Tissue International
- Vol. 81 (2) , 65-72
Circulating Sex Steroids, Sex Hormone-Binding Globulin, and Longitudinal Changes in Forearm Bone Mineral Density in Postmenopausal Women and Men: The Tromsø Study
Bone loss during advancing age in women and men is partly the result of sex steroid deficiency. As the contribution of circulating sex steroids and sex hormone-binding globulin (SHBG) to bone loss remains uncertain, we sought to determine whether levels of sex steroids or SHBG predict change in bone mineral density (BMD) in women and men. A population-based study in the city of Tromsø of 6.5 years’ duration (range 5.4-7.4) included 927 postmenopausal women aged 37–80 years and 894 men aged 25–80 years. Total estradiol and testosterone, calculated free levels, and SHBG were measured at baseline, and BMD change at the distal forearm was determined using BMD measurements in 1994–1995 and 2001. Bone loss was detected in postmenopausal women and men. Free estradiol and SHBG predicted age-adjusted bone loss in postmenopausal women, but only free estradiol was associated after further adjustment for body mass index and smoking in mixed models (P < 0.05). After same adjustment, only SHBG persisted as a significant independent predictor of bone loss in men (P < 0.001). However, only 1% of the variance in bone loss was accounted for by these measurements. We therefore conclude that the relations between sex steroids and bone loss are weak and measurements of sex steroids are unlikely to assist in clinical decision making.
- 1 July 2007
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 157 (1) , 119-125
A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromsø Study
Objectives: As bone fragility is partly the result of sex hormone deficiency, we sought to determine whether circulating sex steroids or sex hormone-binding globulin (SHBG) predicts non-vertebral fractures. Methods: Forearm bone mineral density (BMD), total estradiol and testosterone, calculated free levels, and SHBG were measured in 1386 postmenopausal women and 1364 men aged 50–84 years at baseline in the Tromsø Study (1994–1995). Non-vertebral fractures were documented between 1994 and 2005. Results: During 8.4 years (range 0.01–10.4) of follow-up, 281 women and 105 men suffered non-vertebral fractures. For both sexes, fracture cases had lower BMD and higher SHBG, but sex steroids were not lower. Each standard deviation (s.d.) increase in SHBG increased non-vertebral fracture risk in women (hazards ratio (HR) 1.17; 95% confidence interval (CI) 1.03–1.33) and men (HR 1.26; 95% CI 1.03–1.54). After further adjustment for BMD, the risk was not statistically significant in women (HR 1.09; 95% CI 0.95–1.24) or men (HR 1.22; 95% CI 0.99–1.49). Each s.d. decrease in BMD increased fracture risk in women (HR 1.36; 95% CI 1.19–1.56) and men (HR 1.41; 95% CI 1.15–1.73). Fracture rates were highest in participants with SHBG in the highest tertile and BMD in the lowest tertile and were 37.9 and 17.0 per 1000 person-years in women and men respectively. However, in both sexes the combination of BMD and SHBG was no better predictor of fracture risk than BMD alone. Sex steroids were not associated with fracture risk. Conclusions: Measurements of sex steroids or SHBG are unlikely to assist in decision making regarding fracture risk susceptibility.
- 1 July 2007
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 157 (1) , 119-125
A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromsø Study
Objectives: As bone fragility is partly the result of sex hormone deficiency, we sought to determine whether circulating sex steroids or sex hormone-binding globulin (SHBG) predicts non-vertebral fractures. Methods: Forearm bone mineral density (BMD), total estradiol and testosterone, calculated free levels, and SHBG were measured in 1386 postmenopausal women and 1364 men aged 50–84 years at baseline in the Tromsø Study (1994–1995). Non-vertebral fractures were documented between 1994 and 2005. Results: During 8.4 years (range 0.01–10.4) of follow-up, 281 women and 105 men suffered non-vertebral fractures. For both sexes, fracture cases had lower BMD and higher SHBG, but sex steroids were not lower. Each standard deviation (s.d.) increase in SHBG increased non-vertebral fracture risk in women (hazards ratio (HR) 1.17; 95% confidence interval (CI) 1.03–1.33) and men (HR 1.26; 95% CI 1.03–1.54). After further adjustment for BMD, the risk was not statistically significant in women (HR 1.09; 95% CI 0.95–1.24) or men (HR 1.22; 95% CI 0.99–1.49). Each s.d. decrease in BMD increased fracture risk in women (HR 1.36; 95% CI 1.19–1.56) and men (HR 1.41; 95% CI 1.15–1.73). Fracture rates were highest in participants with SHBG in the highest tertile and BMD in the lowest tertile and were 37.9 and 17.0 per 1000 person-years in women and men respectively. However, in both sexes the combination of BMD and SHBG was no better predictor of fracture risk than BMD alone. Sex steroids were not associated with fracture risk. Conclusions: Measurements of sex steroids or SHBG are unlikely to assist in decision making regarding fracture risk susceptibility.
- Open Access
- 1 October 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (10) , 3798-3802
Seasonal Variation of Estradiol, Follicle Stimulating Hormone, and Dehydroepiandrosterone Sulfate in Women and Men
Context: Seasonal variation in daylight regulates reproduction in animals living at higher latitude, but the influence of season on the sex hormones in humans remains unclear. Objective, Design, and Participants: A cross-sectional population-based study in Tromsø, Norway (70° N) included 1651 women and 1540 men aged 25–84 yr. Circulating total estradiol (and calculated free levels), FSH, and dehydroepiandrosterone sulfate (DHEAS) were measured between September 1994 and September 1995 and provided a unique opportunity to study effects of extreme seasonal variations in the daylight on hormone levels in an arctic population. Main Outcome Measure: Circulating total and free estradiol, FSH, and DHEAS were measured. Results: Total and free estradiol showed differences between monthly means, with peak in June in postmenopausal women (P < 0.001), and in May in men (P = 0.002 and P < 0.001) by analysis of covariance. By cosinor analysis, a seasonal variation in total and free estradiol was evident in women (P = 0.02 and P = 0.03) and men (P = 0.004 and P = 0.001), but only 0.2–0.9% of the variation in total and free estradiol was explained by season. FSH and DHEAS showed no obvious seasonal variation in either sex. Conclusions: Seasonal variations should be considered while designing studies and interpreting results of estradiol measurements to avoid bias in comparative studies.
- 1 October 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (10) , 3798-3802
Open AccessSeasonal Variation of Estradiol, Follicle Stimulating Hormone, and Dehydroepiandrosterone Sulfate in Women and Men
Context: Seasonal variation in daylight regulates reproduction in animals living at higher latitude, but the influence of season on the sex hormones in humans remains unclear. Objective, Design, and Participants: A cross-sectional population-based study in Tromsø, Norway (70° N) included 1651 women and 1540 men aged 25–84 yr. Circulating total estradiol (and calculated free levels), FSH, and dehydroepiandrosterone sulfate (DHEAS) were measured between September 1994 and September 1995 and provided a unique opportunity to study effects of extreme seasonal variations in the daylight on hormone levels in an arctic population. Main Outcome Measure: Circulating total and free estradiol, FSH, and DHEAS were measured. Results: Total and free estradiol showed differences between monthly means, with peak in June in postmenopausal women (P < 0.001), and in May in men (P = 0.002 and P < 0.001) by analysis of covariance. By cosinor analysis, a seasonal variation in total and free estradiol was evident in women (P = 0.02 and P = 0.03) and men (P = 0.004 and P = 0.001), but only 0.2–0.9% of the variation in total and free estradiol was explained by season. FSH and DHEAS showed no obvious seasonal variation in either sex. Conclusions: Seasonal variations should be considered while designing studies and interpreting results of estradiol measurements to avoid bias in comparative studies.
- 1 December 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (12) , 6039-6047
Endogenous Sex Hormones in Relation to Age, Sex, Lifestyle Factors, and Chronic Diseases in a General Population: The Tromsø Study
The role played by endogenous hormones in many diseases makes it important to understand factors influencing their levels. This study examined the distribution of total and free estradiol, FSH, and dehydroepiandrosterone sulfate (DHEAS) by age and sex and associations of these hormones with body mass index (BMI), lifestyle factors, and chronic diseases. Plasma samples taken from 1555 men and 1952 women 25-84 yr of age in 1994-1995 Tromsø Study were analyzed in 2001. Total estradiol increased with age among men (P < 0.001), with or without adjustment for BMI and lifestyle factors. FSH increased with age both in men (P < 0.001) as well as pre- (P < 0.001) and postmenopausal women (P = 0.01) after similar adjustment, and DHEAS decreased with age in both sexes (P < 0.001). With increasing BMI, free estradiol increased in men (P = 0.004), total and free estradiol increased in postmenopausal women (P < 0.001), and FSH decreased in men (P = 0.03) and postmenopausal women (P < 0.001). Men with chronic diseases had lower levels of DHEAS, compared with healthy men (P < 0.001). Smokers had higher DHEAS levels than nonsmokers. Further studies are needed to confirm these hormonal changes with age and disease.
- 1 December 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (12) , 6039-6047
Endogenous Sex Hormones in Relation to Age, Sex, Lifestyle Factors, and Chronic Diseases in a General Population: The Tromsø Study
The role played by endogenous hormones in many diseases makes it important to understand factors influencing their levels. This study examined the distribution of total and free estradiol, FSH, and dehydroepiandrosterone sulfate (DHEAS) by age and sex and associations of these hormones with body mass index (BMI), lifestyle factors, and chronic diseases. Plasma samples taken from 1555 men and 1952 women 25-84 yr of age in 1994-1995 Tromsø Study were analyzed in 2001. Total estradiol increased with age among men (P < 0.001), with or without adjustment for BMI and lifestyle factors. FSH increased with age both in men (P < 0.001) as well as pre- (P < 0.001) and postmenopausal women (P = 0.01) after similar adjustment, and DHEAS decreased with age in both sexes (P < 0.001). With increasing BMI, free estradiol increased in men (P = 0.004), total and free estradiol increased in postmenopausal women (P < 0.001), and FSH decreased in men (P = 0.03) and postmenopausal women (P < 0.001). Men with chronic diseases had lower levels of DHEAS, compared with healthy men (P < 0.001). Smokers had higher DHEAS levels than nonsmokers. Further studies are needed to confirm these hormonal changes with age and disease.
- 30 October 2002
- Vol. 122 (26) , 2536-7
[Postpartum hemorrhage--prophylaxis and treatment in Norway].
Routine oxytocic prophylaxis is known to significantly reduce the risk of severe postpartum haemorrhage (> 1,000 ml) and need for blood transfusion after delivery. To what extent this evidence is implemented in clinical practice in Norway is not known. A telephone questionnaire survey was carried out in September 2001 to evaluate the routine clinical practice for prevention and treatment of postpartum haemorrhage in Norwegian delivery units. Data were available for 55 out of 57 institutions with a delivery unit. Routine third stage prophylaxis with 5-10 IU oxytocin was practiced in 47% of delivery units. Intravenous oxytocin infusion was used primarily in all the delivery units for the treatment of established primary postpartum haemorrhage. 74% of units used methylergometrine, 21% misoprostol as the second-line treatment. Despite evidence for the use of oxytocics for the prevention of postpartum haemorrhage, less than half of delivery units in Norway practice routine prophylaxis in the third stage of labour. Norwegian women may benefit if all maternity care providers implement evidence-based practice.
- 30 October 2002
- Vol. 122 (26) , 2536-7
[Postpartum hemorrhage--prophylaxis and treatment in Norway].
Routine oxytocic prophylaxis is known to significantly reduce the risk of severe postpartum haemorrhage (> 1,000 ml) and need for blood transfusion after delivery. To what extent this evidence is implemented in clinical practice in Norway is not known. A telephone questionnaire survey was carried out in September 2001 to evaluate the routine clinical practice for prevention and treatment of postpartum haemorrhage in Norwegian delivery units. Data were available for 55 out of 57 institutions with a delivery unit. Routine third stage prophylaxis with 5-10 IU oxytocin was practiced in 47% of delivery units. Intravenous oxytocin infusion was used primarily in all the delivery units for the treatment of established primary postpartum haemorrhage. 74% of units used methylergometrine, 21% misoprostol as the second-line treatment. Despite evidence for the use of oxytocics for the prevention of postpartum haemorrhage, less than half of delivery units in Norway practice routine prophylaxis in the third stage of labour. Norwegian women may benefit if all maternity care providers implement evidence-based practice.